These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 22471901

  • 1. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats.
    Shinohara K, Hirooka Y, Ogawa K, Kishi T, Yasukawa K, Utsumi H, Sunagawa K.
    Clin Exp Hypertens; 2012; 34(6):456-62. PubMed ID: 22471901
    [Abstract] [Full Text] [Related]

  • 2. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.
    Shimada K, Ogihara T, Saruta T, Kuramoto K, REZALT Study Group.
    Clin Ther; 2010 May; 32(5):861-81. PubMed ID: 20685495
    [Abstract] [Full Text] [Related]

  • 3. Effects of antihypertensive drugs and exercise training on insulin sensitivity in spontaneously hypertensive rats.
    Guo Q, Minami N, Mori N, Nagasaka M, Ito O, Kurosawa H, Kanazawa M, Kohzuki M.
    Hypertens Res; 2008 Mar; 31(3):525-33. PubMed ID: 18497473
    [Abstract] [Full Text] [Related]

  • 4. Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats.
    Omote Y, Deguchi K, Kono S, Liu W, Kurata T, Hishikawa N, Yamashita T, Ikeda Y, Abe K.
    J Neurosci Res; 2014 Oct; 92(10):1330-7. PubMed ID: 24839960
    [Abstract] [Full Text] [Related]

  • 5. Azelnidipine decreases sympathetic nerve activity via antioxidant effect in the rostral ventrolateral medulla of stroke-prone spontaneously hypertensive rats.
    Konno S, Hirooka Y, Araki S, Koga Y, Kishi T, Sunagawa K.
    J Cardiovasc Pharmacol; 2008 Dec; 52(6):555-60. PubMed ID: 19057394
    [Abstract] [Full Text] [Related]

  • 6. Olmesartan medoxomil and azelnidipine therapy in patients with hypertension and chronic kidney disease in Japan.
    Saito I, Kushiro T, Zenimura N, Matsushita Y, Sagawa K, Hiramatsu K, Yamaguchi F.
    J Nephrol; 2012 Dec; 25(5):699-708. PubMed ID: 22020401
    [Abstract] [Full Text] [Related]

  • 7. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study.
    Daikuhara H, Kikuchi F, Ishida T.
    Diab Vasc Dis Res; 2012 Oct; 9(4):280-6. PubMed ID: 22718810
    [Abstract] [Full Text] [Related]

  • 8. Kidney-protective effects of azelnidipine versus a diuretic in combination with olmesartan in hypertensive patients with diabetes and albuminuria: a randomized study.
    Kojima M, Okubo S, Mizubayashi R, Isaka N, Machida H, Okamoto S, Hirota H, Takeuchi M, Kato T, Nakatani K, Mizuno O, Miyagawa K, Makino K, Okura T, Dohi Y, Ito M, Kimura G.
    Nephrol Dial Transplant; 2013 Jul; 28(7):1802-10. PubMed ID: 23535223
    [Abstract] [Full Text] [Related]

  • 9. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M.
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [Abstract] [Full Text] [Related]

  • 10. Anti-atherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice.
    Noda K, Hosoya M, Nakajima S, Ohashi J, Fukumoto Y, Shimokawa H.
    Tohoku J Exp Med; 2012 Dec; 228(4):305-15. PubMed ID: 23124103
    [Abstract] [Full Text] [Related]

  • 11. Olmesartan reduces oxidative stress in the brain of stroke-prone spontaneously hypertensive rats assessed by an in vivo ESR method.
    Araki S, Hirooka Y, Kishi T, Yasukawa K, Utsumi H, Sunagawa K.
    Hypertens Res; 2009 Dec; 32(12):1091-6. PubMed ID: 19763130
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin-II receptor antagonist combined with calcium channel blocker or diuretic for essential hypertension.
    Ishimitsu T, Numabe A, Masuda T, Akabane T, Okamura A, Minami J, Matsuoka H.
    Hypertens Res; 2009 Nov; 32(11):962-8. PubMed ID: 19696778
    [Abstract] [Full Text] [Related]

  • 13. Long-acting calcium channel blocker, azelnidipine, increases endothelial nitric oxide synthase in the brain and inhibits sympathetic nerve activity.
    Kimura Y, Hirooka Y, Sagara Y, Sunagawa K.
    Clin Exp Hypertens; 2007 Jan; 29(1):13-21. PubMed ID: 17190727
    [Abstract] [Full Text] [Related]

  • 14. Involvement of apoptosis inhibitor of macrophages in a rat hypertension model with nephrosclerosis: possible mechanisms of action of olmesartan and azelnidipine.
    Uramatsu T, Nishino T, Obata Y, Sato Y, Furusu A, Koji T, Miyazaki T, Kohno S.
    Biol Pharm Bull; 2013 Jan; 36(8):1271-7. PubMed ID: 23902971
    [Abstract] [Full Text] [Related]

  • 15. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K, OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group.
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [Abstract] [Full Text] [Related]

  • 16. Comparison of combination therapy of olmesartan plus azelnidipine or hydrochlorothiazide on renal and vascular damage in SHR/NDmcr-cp rats.
    Nagasu H, Satoh M, Yorimitsu D, Tomita N, Sasaki T, Kashihara N.
    Kidney Blood Press Res; 2011 Oct; 34(2):87-96. PubMed ID: 21273789
    [Abstract] [Full Text] [Related]

  • 17. Comparative effect of fixed-dose combination tablets of candesartan cilexetil/amlodipine versus olmesartan medoxomil/azelnidipine on laboratory parameters in patients with hypertension: a retrospective cohort study.
    Susa N, Nishida Y, Yada Y, Nakayama T, Asai S, Takahashi Y.
    Clin Exp Hypertens; 2016 Oct; 38(2):173-9. PubMed ID: 26453437
    [Abstract] [Full Text] [Related]

  • 18. Amlodipine-induced reduction of oxidative stress in the brain is associated with sympatho-inhibitory effects in stroke-prone spontaneously hypertensive rats.
    Hirooka Y, Kimura Y, Nozoe M, Sagara Y, Ito K, Sunagawa K.
    Hypertens Res; 2006 Jan; 29(1):49-56. PubMed ID: 16715653
    [Abstract] [Full Text] [Related]

  • 19. Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study.
    Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K.
    Hypertension; 2012 Jun; 59(6):1132-8. PubMed ID: 22547439
    [Abstract] [Full Text] [Related]

  • 20. The calcium-channel blocker, azelnidipine, enhances the inhibitory action of AT1 receptor blockade on ischemic brain damage.
    Iwai M, Chen R, Ide A, Iwanami J, Tomochika H, Tomono Y, Mogi M, Horiuchi M.
    J Hypertens; 2006 Oct; 24(10):2023-31. PubMed ID: 16957563
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.